Compounds > hispolon
Page last updated: 2024-11-12

hispolon

Description

hispolon: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10082188
CHEMBL ID452722
SCHEMBL ID15917284
SCHEMBL ID20978310
MeSH IDM0270463

Synonyms (17)

Synonym
(3z,5e)-6-(3,4-dihydroxyphenyl)-4-hydroxy-hexa-3,5-dien-2-one
CHEMBL452722
hispolon
AKOS015896251
SCHEMBL15917284
173933-40-9
(3z,5e)-6-(3,4-dihydroxyphenyl)-4-hydroxyhexa-3,5-dien-2-one
hispolon(p)
SCHEMBL20978310
Q15634151
EX-A4869
MS-23223
E88922
CS-0609327
HY-150521
BH171710
DTXSID701045719

Research Excerpts

Overview

Hispolon is a small molecular weight polyphenol that has antioxidant, anti-inflammatory, and anti-proliferative activities. Hispolon (HISP) is a bioactive compound isolated from Phellinu linteus.

ExcerptReferenceRelevance
"Hispolon is a small molecular weight polyphenol derived from Phellinus linteus, which has antioxidant, anti-inflammatory and anti-proliferative activities."( Elucidating the anti-melanoma effect and mechanisms of Hispolon.
Al Saqr, A; Alrbyawi, H; Arnold, RD; Babu, RJ; Dhanasekaran, M; Fujihashi, A; Gottumukkala, S; Govindarajulu, M; Majrashi, M; Poudel, I, 2020)		1.53
"Hispolon is a small molecular weight polyphenol that has antioxidant, anti-inflammatory, and anti-proliferative activities. "( Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells.
Al Saqr, A; Aldawsari, MF; Alrbyawi, H; Annaji, M; Arnold, RD; Babu, RJ; Dhanasekaran, M; Gottumukkala, S; Mulabagal, V; Panizzi, PR; Poudel, I; Ramani, MV; Tiwari, AK, 2020)		2.35
"Hispolon (HISP) is a bioactive compound isolated from Phellinu linteus. "( Hispolon inhibits RANKL induced osteoclast differentiation in vitro.
Adhikari, C; Gawali, B; Khan, A; N P, S; Naidu, V; P A, S; Rajdev, B; Sharma, P; Thimmuri, D; V, R, 2021)		3.51
"Hispolon is a polyphenolic compound isolated from Phellinus linteus which exhibits antitumor activity. "( Effects of hispolon on glioblastoma cell growth.
Arcella, A; Cantore, G; Esposito, V; Giangaspero, F; Oliva, MA; Sanchez, M; Staffieri, S, 2017)		2.29
"Hispolon (HIS) is an active polyphenol compound derived from Phellinus linteus (Berkeley & Curtis), and our previous study showed that HIS effectively inhibited inflammatory responses in macrophages [Yang, L.Y., S.C. "( Hispolon Suppresses LPS- or LTA-Induced iNOS/NO Production and Apoptosis in BV-2 Microglial Cells.
Chen, YC; Cheng, KT; Chien, CC; Subbaraju, GV; Wu, MS, 2017)		3.34
"Hispolon is a polyphenolic compound derived from black hoof mushroom ("( Developing Hispolon-based novel anticancer therapeutics against human (NF-κβ) using
Kumar Panda, M; Paul, M; Thatoi, H, 2019)		2.35
"Hispolon is an active phenolic compound of Phellinus igniarius, a mushroom that was recently shown to have antioxidant and anticancer activities in various solid tumors. "( Hispolon induces apoptosis through JNK1/2-mediated activation of a caspase-8, -9, and -3-dependent pathway in acute myeloid leukemia (AML) cells and inhibits AML xenograft tumor growth in vivo.
Chen, HY; Chien, MH; Chow, JM; Hsiao, M; Hsiao, PC; Hsieh, YH; Hua, KT; Lin, CH; Yang, SF, 2013)		3.28
"Hispolon is an active phenolic compound of Phellinus linteus, a mushroom that has recently been shown to have antioxidant and anticancer activities."( Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways.
Amagaya, S; Chang, YS; Hou, WC; Hu, ML; Huang, GJ; Huang, SS; Wang, HC; Yang, CM, 2010)		2.52
"Hispolon is an active phenolic compound of Phellinus igniarius , a mushroom that has recently been shown to have antioxidant, anti-inflammatory, and anticancer activities. "( Hispolon induces apoptosis and cell cycle arrest of human hepatocellular carcinoma Hep3B cells by modulating ERK phosphorylation.
Deng, JS; Hu, ML; Huang, GJ; Huang, SS, 2011)		3.25

Effects

Hispolon has been shown to have anticancer effects on various tumors. Hispolon is a polyphenol. It has been reported to possess antioxidant, antiinflammatory, and antitumor activities.

ExcerptReferenceRelevance
"Hispolon has been reported to induce apoptosis in gastric cancer, hepatocellular carcinoma, and myeloid leukemia."( Elucidating the anti-melanoma effect and mechanisms of Hispolon.
Al Saqr, A; Alrbyawi, H; Arnold, RD; Babu, RJ; Dhanasekaran, M; Fujihashi, A; Gottumukkala, S; Govindarajulu, M; Majrashi, M; Poudel, I, 2020)		1.53
"Hispolon, a polyphenol has been reported to possess anticancer, antidiabetic, antioxidant, antiviral and anti-inflammatory activities."( Hispolon: A natural polyphenol and emerging cancer killer by multiple cellular signaling pathways.
Adem, Ş; Hussain, G; Li, X; Masood, M; Rasul, A; Sarfraz, A; Sarfraz, I; Sarker, SD; Shafiq, N; Shah, MA, 2020)		2.72
"Hispolon has been found to have phytoestrogenic properties."( Effect of Hispolon from Phellinus lonicerinus (Agaricomycetes) on Estrogen Receptors, Aromatase, and Cyclooxygenase II in MCF-7 Breast Cancer Cells.
Chen, B; He, H; Hu, F; Huang, W; Wang, J; Yu, H; Zhang, H; Zou, X, 2017)		1.58
"Hispolon has been shown to have anticancer effects on various tumors. "( Hispolon inhibits breast cancer cell migration by reversal of epithelial-to-mesenchymal transition via suppressing the ROS/ERK/Slug/E-cadherin pathway.
Chen, W; Li, YQ; Lv, LX; Sun, YS; Zhao, Z, 2016)		3.32
"Hispolon has been reported to possess antioxidant, antiinflammatory, and antitumor activities. "( Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway.
Chuang, CY; Ho, HY; Ho, YC; Hsieh, MJ; Hsin, CH; Lin, CW; Yang, SF, 2017)		3.34

Actions

Hispolon could increase the body weight coefficient, serum E2 and progesterone contents in immature female mice at dose of 9.10×10(-6) mol/kg. Hispolon was shown to increase the serum 17β-estradiol in vivo.

ExcerptReferenceRelevance
"Hispolon was shown to increase the serum 17β-estradiol in vivo."( Effect of Hispolon from Phellinus lonicerinus (Agaricomycetes) on Estrogen Receptors, Aromatase, and Cyclooxygenase II in MCF-7 Breast Cancer Cells.
Chen, B; He, H; Hu, F; Huang, W; Wang, J; Yu, H; Zhang, H; Zou, X, 2017)		1.58
"Hispolon could increase the body weight coefficient, serum E2 and progesterone contents in immature female mice at dose of 9.10×10(-6) mol/kg, and increase coefficient of thymus and spleen in mice."( Estrogenic and anti-estrogenic activities of hispolon from Phellinus lonicerinus (Bond.) Bond. et sing.
Cheng, F; Deng, W; Deng, Z; Hu, F; Huang, N; Luo, H; Luo, Y; Wang, J; Zou, K, 2014)		1.38

Treatment

Hispolon treatment also inhibited expression of the ERα target gene pS2. Treatment also activated JNK, p38 MAPK, and ERK expression.

ExcerptReferenceRelevance
"In hispolon-treated tumors, activation of caspase-3 and a decrease in Ki67-positive cells were observed."( Hispolon induces apoptosis through JNK1/2-mediated activation of a caspase-8, -9, and -3-dependent pathway in acute myeloid leukemia (AML) cells and inhibits AML xenograft tumor growth in vivo.
Chen, HY; Chien, MH; Chow, JM; Hsiao, M; Hsiao, PC; Hsieh, YH; Hua, KT; Lin, CH; Yang, SF, 2013)		2.35
"Hispolon treatment also inhibited expression of the ERα target gene pS2."( Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha.
Cho, IH; Hong, D; Jang, EH; Jang, SY; Jung, B; Kim, JH; Park, MJ, 2015)		2.58
"Hispolon treatment also activated JNK, p38 MAPK, and ERK expression."( Hispolon induces apoptosis and cell cycle arrest of human hepatocellular carcinoma Hep3B cells by modulating ERK phosphorylation.
Deng, JS; Hu, ML; Huang, GJ; Huang, SS, 2011)		2.53

Bioavailability

ExcerptReferenceRelevance
"Hispolon, a phenolic pigment isolated from the mushroom species Phellinus linteus, has been investigated for anti-inflammatory, antioxidant, and anticancer properties; however, low solubility and poor bioavailability have limited its potential clinical translation."( Hispolon Cyclodextrin Complexes and Their Inclusion in Liposomes for Enhanced Delivery in Melanoma Cell Lines.
Annaji, M; Arnold, RD; Babu, RJ; Dhanasekaran, M; Fasina, O; Peresin, MS; Poudel, I; Rangari, V; Smith, F; Tiwari, AK; Via, B; Wibowo, FS, 2022)		3.61
"6 W/Kg specific absorption rate (SAR) in call-answered mode treated with HIS and its derivatives."( Protective role of hispolon and its derivatives against apoptosis in cortical neurons induced by electromagnetic radiation from 4G mobile phone.
Narayanasamy, D; Saka, VP; V, C, 2023)		1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1194886Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID1194887Cytotoxicity against HEK293 cells expressing pcDNA3.1 after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID401946Cytotoxicity against human A549 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID689638Inhibition of FAK-mediated ERK1 phosphorylation in rat A10 cells after 30 mins by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689639Inhibition of FAK-mediated ERK2 phosphorylation in rat A10 cells after 30 mins by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194901Cytotoxicity against HEK293 cells expressing ABCB1 after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID1194880Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID401949Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID689508Antiproliferative activity against rat A10 cells after 24 hrs by MTT assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194881Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID689509Antiproliferative activity against rat A10 cells at 5 to 25 ug/mL after 24 hrs by MTT assay relative to control2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194885Cytotoxicity against MDCK cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID689506Antirestenotic activity in Sprague-Dawley rat assessed as reduction in balloon injury-induced neointimal:medium area ratio in carotid artery at 20 mg/mL, administered topically measured after 2 weeks by hematoxylin and eosin staining method relative to ve2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689635Upregulation of TIMP1 expression in rat A10 cells after 24 hrs by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689629Inhibition of FAK-mediated FBS-induced cell migration of rat A10 cells at 10 ug/mL after 18 hrs by scratch-wound assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689631Inhibition of FAK-mediated FBS-induced cell migration of rat A10 cells at 20 ug/mL after 18 hrs by scratch-wound assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID402203Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID1194882Cytotoxicity against human S1 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID689636Upregulation of TIMP2 expression in rat A10 cells after 24 hrs by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689637Inhibition of FAK phosphorylation in rat A10 cells after 24 hrs by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689640Inhibition of FAK in rat A10 cells assessed as inhibition of serum-induced AKT phosphorylation after 24 hrs by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194884Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID401947Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID689507Antirestenotic activity in Sprague-Dawley rat assessed as reduction in balloon injury-induced PCNA expression in carotid artery at 10 and 20 mg/mL, administered topically measured after 2 weeks by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689630Inhibition of FAK-mediated FBS-induced cell migration of rat A10 cells at 15 ug/mL after 18 hrs by scratch-wound assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689510Antiproliferative activity against rat A10 cells at 30 to 40 ug/mL after 24 hrs by MTT assay relative to control2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689511Induction of cell cycle arrest in rat A10 cells assessed as S phase cells at 10 to 40 ug/mL after 24 hrs by PI-staining based flow cytometric analysis relative to vehicle-treated control2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689641Inhibition of FAK in rat A10 cells assessed as inhibition of serum-induced PI3K expression after 24 hrs by Western blot analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689633Inhibition of FAK-mediated MMP2 activity in rat A10 cells after 24 hrs by zymographic analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689505Antirestenotic activity in Sprague-Dawley rat assessed as reduction in balloon injury-induced neointimal:medium area ratio in carotid artery at 10 mg/mL, administered topically measured after 2 weeks by hematoxylin and eosin staining method relative to ve2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194883Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID402279Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID401948Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay2004Journal of natural products, May, Volume: 67, Issue:5
Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius.
AID1194879Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID689628Induction of apoptosis in rat A10 cells assessed as sub-G1 cells at 10 to 40 ug/mL after 24 hrs by PI-staining based flow cytometric analysis relative to vehicle-treated control2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID689634Inhibition of FAK-mediated MMM9 activity in rat A10 cells after 24 hrs by zymographic analysis2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
AID1194902Resistance index, ratio of IC50 for HEK293 cells expressing ABCB1 to IC50 for HEK293 cells expressing pcDNA3.12015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.
AID689632Inhibition of FAK-mediated FBS-induced migration of rat A10 cells at 15 and 20 ug/mL after 18 hrs by transwell assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hispolon attenuates balloon-injured neointimal formation and modulates vascular smooth muscle cell migration via AKT and ERK phosphorylation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.96)18.2507
2000's5 (9.80)29.6817
2010's31 (60.78)24.3611
2020's14 (27.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.04 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index5.64 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
temozolomide
[no description available]		3.4110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
thymidine
[no description available]		1.9910pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		2.110anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		7.5720isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
aloe emodin
aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.		3.4110aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		7.2510metal allergen;
nickel group element atom;
platinum group metal atom
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.0210pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		1.9910D-glucopyranoseepitope;
mouse metabolite
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		7.0510aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
bay 11-7082
(E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.		2.110nitrile;
sulfone		apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
inotilone
inotilone: structure in first source		2.0610
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0310
hispidin
hispidin: metabolite of Basidiomycete Polyporus hispidus. hispidin : Fungal metabolite first found in basidiomycete Inonotus hispidus (formerly Polyporus hispidus).		7.95402-pyranones;
catechols		antioxidant;
EC 2.7.11.13 (protein kinase C) inhibitor;
fungal metabolite
phytoestrogens
Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.		2.5820
lactoferrin
Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.		3.4110
lipoteichoic acid
lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.		2.5220
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		02.0710
Degenerative Diseases, Central Nervous System
[description not available]		02.4110
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		02.4110
Malignant Melanoma
[description not available]		04.11110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		04.11110
Bladder Cancer
[description not available]		07.5220
Carcinoma, Anaplastic
[description not available]		02.8630
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.5220
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.8630
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.610
Carcinoma, Epidermoid
[description not available]		02.610
Cancer of Head
[description not available]		02.610
Cancer of Mouth
[description not available]		02.610
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.610
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.610
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.610
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.610
Cancer of Prostate
[description not available]		02.2110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.2110
B16 Melanoma
[description not available]		02.2510
Cancer of Skin
[description not available]		02.2510
Skin Neoplasms
Tumors or cancer of the SKIN.		02.2510
Lung Injury, Acute
[description not available]		02.2510
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		07.2510
Benign Neoplasms
[description not available]		03.1710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.1710
Benign Neoplasms, Brain
[description not available]		04.4520
Astrocytoma, Grade IV
[description not available]		04.7630
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		04.4520
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		04.7630
Cancer of Cervix
[description not available]		02.1510
Metastase
[description not available]		02.4920
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.1510
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.4920
Aging, Premature
Changes in the organism associated with senescence, occurring at an accelerated rate.		02.2110
Acute Myelogenous Leukemia
[description not available]		02.0810
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.0810
Leucocythaemia
[description not available]		02.0810
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.110
Innate Inflammatory Response
[description not available]		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110
Cancer of Lung
[description not available]		02.110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.110
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		02.5220
Cancer of Nasopharynx
[description not available]		02.5220
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		02.5220
Breast Cancer
[description not available]		02.7830
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.7830
Invasiveness, Neoplasm
[description not available]		02.1510
Hepatocellular Carcinoma
[description not available]		07.4620
Cancer of Liver
[description not available]		02.4620
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.4620
Liver Neoplasms
Tumors or cancer of the LIVER.		02.4620
Cancer of Stomach
[description not available]		02.0410
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.0410
chemdatabank.com